Abstract
Aims: Recent data have demonstrated the feasibility of therapeutic induction of coronary collateral growth (arteriogenesis); however, mechanisms of action of such therapeutic collateral stimulation in humans are unknown. The aim of this study was to evaluate potential mechanisms, especially the involvement of arteriogenesis-relevant genes. Methods and Results: A total of 52 patients were randomized into two groups: subcutaneous G-CSF (10μg/kg; n=26) or placebo (n=26). Before and after this 2-week treatment, collateral-flow index (CFI) was determined by simultaneous measurement of mean aortic, distal coronary occlusive and central venous pressure. CD34+ endothelial progenitor cells (EPC) and monocytes were quantified before, during and after treatment; gene-expression analysis of monocytes was performed with real-time polymerase chain reaction (RT-PCR). G-CSF lead to a significant increase of EPC and monocytes (4.8 and 2.6 fold, p<0.05); for both cell types, the extent of increase correlated with CFI increase (r=0.23 and 0.14, p<0.05). G-CSF also induced a change in gene expression of pro-and anti-arteriogenic genes in monocytes. Among nine assessed genes, three were found to be differentially regulated (IL8, JAK2, and PNPLa4; p<0.05). Conclusions: The mechanism of induction of collateral growth by G-CSF is related to an increase of EPC and of peripheral monocytes. It also leads to a change toward a pro-arteriogenic gene expression in peripheral monocytes.
Keywords: Arteriogenesis, collateral circulation, granulocyte-colony stimulating factor, endothelial progenitor cells, monocytes, gene expression
Current Vascular Pharmacology
Title:G-CSF Induced Arteriogenesis in Humans: Molecular Insights into a Randomized Controlled Trial
Volume: 11 Issue: 1
Author(s): Pascal Meier, Steffen Gloekler, Berna Oezdemir, Andreas Indermuehle, Tobias Traupe, Rolf Vogel, Stefano de Marchi and Christian Seiler
Affiliation:
Keywords: Arteriogenesis, collateral circulation, granulocyte-colony stimulating factor, endothelial progenitor cells, monocytes, gene expression
Abstract: Aims: Recent data have demonstrated the feasibility of therapeutic induction of coronary collateral growth (arteriogenesis); however, mechanisms of action of such therapeutic collateral stimulation in humans are unknown. The aim of this study was to evaluate potential mechanisms, especially the involvement of arteriogenesis-relevant genes. Methods and Results: A total of 52 patients were randomized into two groups: subcutaneous G-CSF (10μg/kg; n=26) or placebo (n=26). Before and after this 2-week treatment, collateral-flow index (CFI) was determined by simultaneous measurement of mean aortic, distal coronary occlusive and central venous pressure. CD34+ endothelial progenitor cells (EPC) and monocytes were quantified before, during and after treatment; gene-expression analysis of monocytes was performed with real-time polymerase chain reaction (RT-PCR). G-CSF lead to a significant increase of EPC and monocytes (4.8 and 2.6 fold, p<0.05); for both cell types, the extent of increase correlated with CFI increase (r=0.23 and 0.14, p<0.05). G-CSF also induced a change in gene expression of pro-and anti-arteriogenic genes in monocytes. Among nine assessed genes, three were found to be differentially regulated (IL8, JAK2, and PNPLa4; p<0.05). Conclusions: The mechanism of induction of collateral growth by G-CSF is related to an increase of EPC and of peripheral monocytes. It also leads to a change toward a pro-arteriogenic gene expression in peripheral monocytes.
Export Options
About this article
Cite this article as:
Meier Pascal, Gloekler Steffen, Oezdemir Berna, Indermuehle Andreas, Traupe Tobias, Vogel Rolf, de Marchi Stefano and Seiler Christian, G-CSF Induced Arteriogenesis in Humans: Molecular Insights into a Randomized Controlled Trial, Current Vascular Pharmacology 2013; 11 (1) . https://dx.doi.org/10.2174/1570161111309010038
DOI https://dx.doi.org/10.2174/1570161111309010038 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis, Anticonvulsant and Antimicrobial Activities of Some New [1-(2-Naphthyl)-2-(pyrazol-1-yl)ethanone]oxime Ethers
Medicinal Chemistry Oral Antiplatelet Agents and Bleeding Risk in Relation to Major Cardiovascular Surgery
Current Drug Safety Outcomes of Anticoagulant Therapy with Low-Molecular-Weight Heparin (LMWH) and Warfarin for Thromboangiitis Obliterans (TAO)
Current Vascular Pharmacology Transcranial Direct Current Stimulation - An Adjuvant Tool for the Treatment of Neuropsychiatric Diseases?
Current Psychiatry Reviews Withdrawal Notice: Ionic Liquid Mediated Synthesis of Schiff bases Bearing Thiazole and Indole Moieties
Current Organic Synthesis Platelets Structure, Function and Modulator Capacity in Replacement Therapy
Cardiovascular & Hematological Disorders-Drug Targets Thrombotic Complications of Neonates and Children with Congenital Nephrotic Syndrome
Current Pediatric Reviews Pitavastatin Combined with Ezetimibe Treatment was an Effective Approach to Non-IRA Lesion of ST-segment Elevation Myocardial Infarction Patients with Primary Percutaneous Coronary Intervention
Current Pharmaceutical Biotechnology Evaluation of Novel 7-(hetero)aryl-substituted Pyrazolo[1, 5-a]pyrimidines as Phosphodiesterase-4 Inhibitors
Letters in Drug Design & Discovery Nephroangiosclerosis and Its Pharmacological Approach
Current Vascular Pharmacology MicroRNA-136 Promotes Vascular Muscle Cell Proliferation Through the ERK1/2 Pathway by Targeting PPP2R2A in Atherosclerosis
Current Vascular Pharmacology Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry Vasotrophic Regulation of Age-Dependent Hypoxic Cerebrovascular Remodeling
Current Vascular Pharmacology EDITORIAL (Thematic Issue: Novel Oral Anticoagulation-A Milestone in Anticoagulation History)
Cardiovascular & Hematological Disorders-Drug Targets Getting Patients to Target- Implementing the Guidelines
Current Vascular Pharmacology The hERG Channel and Risk of Drug-Acquired Cardiac Arrhythmia: An Overview
Current Topics in Medicinal Chemistry Adjunctive Strategies in the Management of Resistant, ‘Undilatable’ Coronary Lesions After Successfully Crossing a CTO with a Guidewire
Current Cardiology Reviews Inflammation: A Link Between Hypertension and Atherosclerosis
Current Hypertension Reviews Post-stroke Engagement-sensitive Balance Rehabilitation Under An Adaptive Multi-level Electrotherapy: Clinical Hypothesis and Computational Framework
Neuroscience and Biomedical Engineering (Discontinued) Ketamine and Glutamate Receptors: Potential Toxicity of General Anesthetics during Rapid Brain Development
Central Nervous System Agents in Medicinal Chemistry